Thomas M Roberts

List of Publications by Year
in descending order

80 papers	14,146 citations	71102 41 h-index	71685 76 g-index
83 all docs	83 docs citations	83 times ranked	18947 citing authors

#	Article	IF	Citations
1	PCTAIRE1 promotes mitotic progression and resistance against antimitotic and apoptotic signals. Journal of Cell Science, 2022, 135, .	2.0	2
2	Blocking PI3K p110Î² Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2022, 20, 673-685.	3.4	6
3	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 2022, 13, .	12.8	68
4	Genetic ablation of <scp>FASN</scp> attenuates the invasive potential of prostate cancer driven by <scp>Pten</scp> loss. Journal of Pathology, 2021, 253, 292-303.	4.5	13
5	The role of the PIK3CA gene in the development and aging of the brain. Scientific Reports, 2021, 11, 291.	3.3	3
6	TMTpro-18plex: The Expanded and Complete Set of TMTpro Reagents for Sample Multiplexing. Journal of Proteome Research, 2021, 20, 2964-2972.	3.7	158
7	Multi-targeting siRNA nanoparticles for simultaneous inhibition of PI3K and Rac1 in PTEN-deficient prostate cancer. Journal of Industrial and Engineering Chemistry, 2021, 99, 196-203.	5.8	5
8	Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. , 2021, 9, e002474.		34
9	The Mediator captures CDK7, an attractive transcriptional target in cancer. Cancer Cell, 2021, 39, 1184-1186.	16.8	2
10	RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics, 2021, 13, 1638.	4.5	10
11	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene, 2020, 39, 50-63.	5.9	43
12	Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. Journal of Controlled Release, 2020, 318, 98-108.	9.9	27
13	Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Reports, 2020, 32, 108196.	6.4	13
14	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-Î± inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24427-24433.	7.1	12
15	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cellâ€“Level PI3K Pathway Activation. Clinical Cancer Research, 2020, 26, 5903-5913.	7.0	8
16	Polyomavirus Small T Antigen Induces Apoptosis in Mammalian Cells through the UNC5B Pathway in a PP2A-Dependent Manner. Journal of Virology, 2020, 94, .	3.4	8
17	The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules, 2019, 9, 713.	4.0	17
18	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	1.6	103

#	Article	IF	Citations
19	PI3K alpha and delta promote hematopoietic stem cell activation. JCI Insight, 2019, 4, .	5.0	31
20	Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. Journal of Clinical Oncology, 2018, 36, 1339-1342.	1.6	11
21	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5.	6.4	381
22	A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. IScience, 2018, 9, 149-160.	4.1	12
23	Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9325-E9332.	7.1	28
24	Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget, 2018, 9, 23878-23889.	1.8	11
25	PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress. Blood, 2018, 132, 329-329.	1.4	0
26	PI3K-p110Î± mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85Î±. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7095-7100.	7.1	75
27	Epigenetic regulation of RTK signaling. Journal of Molecular Medicine, 2017, 95, 791-798.	3.9	19
28	The metabolic function of cyclin D3â€“CDK6 kinase in cancer cell survival. Nature, 2017, 546, 426-430.	27.8	276
29	The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 123-131.	7.4	117
30	CRKL Mediates p110Î²-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Reports, 2017, 20, 549-557.	6.4	33
31	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	27.8	998
32	Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology, 2017, 19, 22-30.	1.2	32
33	Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP. Journal of Virology, 2016, 90, 7032-7045.	3.4	13
34	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecologic Oncology, 2016, 142, 548-556.	1.4	80
35	NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3Kâ€“AKT and JAKâ€“STAT3 pathways. Cell Discovery, 2016, 2, 16030.	6.7	17
36	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	30.7	105

#	Article	IF	Citations
37	Delivery strategies and potential targets for siRNA in major cancer types. Advanced Drug Delivery Reviews, 2016, 104, 2-15.	13.7	100
38	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	6.4	92
39	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget, 2016, 7, 13153-13166.	1.8	66
40	Rac1-mediated membrane raft localization of PI3K/p110Î² is required for its activation by GPCRs or PTEN loss. ELife, 2016, 5, .	6.0	25
41	Papillomavirus E7 Oncoproteins Share Functions with Polyomavirus Small T Antigens. Journal of Virology, 2015, 89, 2857-2865.	3.4	17
42	A PI3K p110Î²â€“Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications, 2015, 6, 8501.	12.8	44
43	Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110Î±. Journal of Clinical Investigation, 2014, 124, 1794-1809.	8.2	48
44	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6395-6400.	7.1	66
45	The Phosphatidylinositol 3-Kinase (PI3K) Isoform Dependence of Tumor Formation Is Determined by the Genetic Mode of PI3K Pathway Activation Rather than by Tissue Type. Journal of Virology, 2014, 88, 10673-10679.	3.4	10
46	Polyomavirus Small t Antigen Interacts with Yes-Associated Protein To Regulate Cell Survival and Differentiation. Journal of Virology, 2014, 88, 12055-12064.	3.4	24
47	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell, 2014, 158, 171-184.	28.9	608
48	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. Cancer Discovery, 2013, 3, 44-51.	9.4	47
49	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110Î² as a Potential Anticancer Agent. Cancer Discovery, 2012, 2, 425-433.	9.4	152
50	The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes and Development, 2012, 26, 1573-1586.	5.9	116
51	Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma. Journal of Virology, 2011, 85, 5581-5592.	3.4	5
52	Comparisons between Murine Polyomavirus and Simian Virus 40 Show Significant Differences in Small T Antigen Function. Journal of Virology, 2011, 85, 10649-10658.	3.4	22
53	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468, 968-972.	27.8	1,325
54	A constitutively activated form of the p110Î² isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11002-11007.	7.1	57

#	Article	IF	Citations
55	Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology, 2009, 384, 304-316.	2.4	45
56	Should individual PI3 kinase isoforms be targeted in cancer?. Current Opinion in Cell Biology, 2009, 21, 199-208.	5.4	106
57	Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 2009, 8, 627-644.	46.4	2,218
58	The p110Î± Catalytic Isoform of PI3 Kinase Is Important for Erythropoiesis, but Has a Minimal Role in Hematopoietic Stem Cell Self-Renewal.. Blood, 2009, 114, 3620-3620.	1.4	0
59	Essential roles of PI(3)Kâ€“p110Î² in cell growth, metabolism and tumorigenesis. Nature, 2008, 454, 776-779.	27.8	654
60	The Identification of Zebrafish Mutants Showing Alterations in Senescence-Associated Biomarkers. PLoS Genetics, 2008, 4, e1000152.	3.5	132
61	A Non-Canonical Function of Zebrafish Telomerase Reverse Transcriptase Is Required for Developmental Hematopoiesis. PLoS ONE, 2008, 3, e3364.	2.5	47
62	Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19011-19016.	7.1	94
63	The p110Î± Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation. Journal of Virology, 2007, 81, 7069-7076.	3.4	28
64	Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. Cell, 2007, 129, 1065-1079.	28.9	538
65	The p110Â isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16296-16300.	7.1	201
66	The oncogenic properties of mutant p110Â and p110Â phosphatidylinositol 3-kinases in human mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18443-18448.	7.1	313
67	A new class of mutations reveals a novel function for the original phosphatidylinositol 3-kinase binding site. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9434-9439.	7.1	8
68	The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity. Oncogene, 2000, 19, 3961-3970.	5.9	16
69	Mapping of polyomavirus middle T domain that is responsible for AP-1 activation. Oncogene, 1998, 16, 2975-2982.	5.9	7
70	Serine 257 Phosphorylation Regulates Association of Polyomavirus Middle T Antigen with 14-3-3 Proteins. Journal of Virology, 1998, 72, 558-563.	3.4	38
71	Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase. Science, 1997, 276, 1848-1850.	12.6	398
72	A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. , 1996, 66, 753-759.		2

#	Article	IF	Citations
73	Association of Polyomavirus Middle Tumor Antigen with Phospholipase C-Î³1. Journal of Biological Chemistry, 1995, 270, 12331-12334.	3.4	87
74	A signal chain of events. Nature, 1992, 360, 534-535.	27.8	208
75	Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell, 1990, 60, 167-176.	28.9	628
76	The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase. Nature, 1989, 342, 699-702.	27.8	354
77	Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature, 1988, 336, 738-744.	27.8	294
78	Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell, 1987, 49, 75-82.	28.9	582
79	Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell, 1987, 50, 1021-1029.	28.9	708
80	Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature, 1985, 315, 239-242.	27.8	845